论文部分内容阅读
目的:检测肺癌患者呼出气冷凝液中p16基因异常甲基化情况,探讨呼出气冷凝液中p16基因异常甲基化改变作为肺癌临床辅助诊断分子生物学标志物的可能性。方法:利用甲基化特异性聚合酶链反应(MS-PCR)方法,检测20例病理确诊肺癌患者的呼出气冷凝液标本中p16基因的甲基化情况。结果:20例确诊肺癌患者呼出气冷凝液中p16基因异常甲基化阳性例数为8例(40.0%),其中肺鳞癌、腺癌、小细胞癌患者呼出气冷凝液标本的阳性率分别为40.0%,33.3%和50.0%。p16基因的甲基化异常改变与肿瘤的分期、分型无明显相关性。但是呼出气冷凝液中p16基因甲基化水平均为部分甲基化状态。结论:用呼出气冷凝液标本检测甲基化来诊断和筛选肺癌,p16基因可能不是一个理想的候选基因。
Objective: To detect the abnormal methylation of p16 gene in exhaled breath condensate of patients with lung cancer, and to explore the possibility of abnormal methylation of p16 gene in exhaled breath condensate as a clinical molecular diagnostic biomarker for lung cancer. Methods: Methylation-specific polymerase chain reaction (MS-PCR) was used to detect the methylation of p16 gene in exhaled breath condensate from 20 pathologically confirmed lung cancer patients. Results: The positive rate of abnormal methylation of p16 gene in exhaled breath condensate of 20 patients diagnosed with lung cancer was 8 (40.0%). The positive rates of expired air condensate samples in lung squamous cell carcinoma, adenocarcinoma and small cell carcinoma were 40.0%, 33.3% and 50.0%. The abnormal methylation of p16 gene had no significant correlation with tumor stage and type. However, the methylation levels of p16 gene in expired air condensate were all partially methylated. CONCLUSION: The p16 gene may not be an ideal candidate for the diagnosis and screening of lung cancer by exhaled breath condensate samples for methylation detection.